The tumor suppressor p53-related p73 shares significant amino-acid sequence identity with p53. Like p53, p73 recognizes canonical p53 DNA-binding sites and activates p53-responsive target genes and induces apoptosis. Moreover, transcription coactivator p300/CBP binds to and coactivates with both p53 and p73 in stimulating the expression of their target genes. Here, we report that coactivator PCAF binds to p73. The N-terminal transactivation domain (TAD) and the conserved oligomerization domain (OD) of p73 are both required for its interaction with PCAF. Conversely, PCAF's HAT-domain is required for and both the N-terminal region and Bromo domain enhance binding of PCAF to p73. Significantly, PCAF stimulates p73-mediated transactivation, and binding of PCAF to p73 is necessary for p73's transactivation activity. PCAF-specific siRNA dramatically reduces p73-mediated transactivation. Stimulation of p73-mediated transactivation by PCAF requires the HAT domain of PCAF and the p53-binding site within the p21 promoter. In vivo, coexpression of wild-type, but not HAT-deficient PCAF with p73b markedly increases p21 expression. Furthermore, cotransfection of PCAF and p73 leads to increased apoptosis and reduced colony formation. Collectively, these data suggest that p73 recruit PCAF to specific promoters to activate the transcription of p73 target genes.
Introduction
p53 is a tumor suppressor whose inactivation is observed in most human cancers (Levine, 1997; Prives and Hall, 1999; Vogelstein et al., 2000) . p53 plays a central role in regulating cell growth, particularly in response to various forms of stress including DNA damage and viral infection, because p53 sits on a critical node of signal transduction networks that control cell growth and death. p53 exerts its tumor suppressor function, to a large extent, by regulating expression of genes that control cell-cycle progression and apoptosis (Yu et al., 1999; Vousden, 2000; Zhao et al., 2000) . Three specific domains of p53 contribute to its transactivation activity: the N-terminal transactivation domain (TAD), the central sequence-specific DNA-binding domain (DBD) and the C-terminal regulatory domain (RD). The TAD contacts several transcriptional regulators, including components of the RNA polymerase II transcriptional machinery, such as TFIID, TFIIH and the transcriptional coactivators p300 and CREB-binding protein (CBP). The DBD recognizes and binds to a specific consensus sequence, four copies of pentamer PuPuPuC(A/T) oriented in alternating directions (el-Deiry et al., 1992) , which has been identified in an increasing number of p53 target genes (Yu et al., 1999; Zhao et al., 2000; Stambolic et al., 2001) .
Several p53-like proteins including the p73 and p63 families of proteins have been reported in recent years (Yang and McKeon, 2000) . These proteins resemble p53 in both sequence and function. Like p53, p73 contains TAD in its N-terminal domain, DBD in the central portion, which is followed by an oligomerization domain (OD), and it ends with domains in the Cterminal region that may play various regulatory roles (Kaghad et al., 1997; Arrowsmith, 1999; Marin and Kaelin, 2000; Yang and McKeon, 2000) . p73 can bind to the consensus p53-binding DNA and activate the expression of genes containing such a sequence as well as induction of apoptosis (Kaghad et al., 1997; Marin et al., 1998; Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999; Irwin et al., 2000) . Also, both p53 and p73 are known to use p300/CBP as a coactivator (Avantaggiati et al., 1997; Zeng et al., 2000) . However, the p53 superfamily of proteins displays remarkable structural and functional differences (Yang and McKeon, 2000) . One conspicuous difference between p53 and p73 is that the p53 gene gives rise to only one product, whereas the p73 gene produces over six variants (Kaghad et al., 1997; Marin and Kaelin, 2000; Yang and McKeon, 2000) . All known p73 isoforms retain the DBD and OD, but alternative transcription initiation and splicing of p73 mRNA result in isoforms that have different N-and C-terminal alterations Yang and McKeon, 2000) . Moreover, unlike p53, which is phosphorylated by DNAPK and ATM (Ko and Prives, 1996; Prives and Hall, 1999) , the p73 protein accumulates and undergoes c-Abl-dependent tyrosine phosphorylation in response to DNA damage (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999) . Furthermore, p73 is not targeted for inactivation by viral oncoproteins such as simian virus 40 T antigen, adenovirus E1B 55-kDa and human papillomavirus E6 (Higashino et al., 1998; Marin et al., 1998; Prabhu et al., 1998; Wienzek et al., 2000; Gu et al., 2001; Querido et al., 2001) , although cellular oncoprotein MDM2 was shown to inhibit p73-mediated transactivation (Kobet et al., 2000) .
The extended C-terminal region of p73a, which is not present in p53, has a motif similar to sterile alpha motif (SAM). This motif is involved in protein-protein interactions (Arrowsmith, 1999) . It has been shown that the C-terminal region of p73a may negatively regulate p53-like activities of p73. For example, p73b, which lacks much of the extended C-terminal domain including SAM, is more active as a transcriptional transactivator of some p53-responsive reporter genes (De Laurenzi et al., 1998; Minty et al., 2000) . As a protein-protein interaction module, SAM can potentially recruit proteins, thereby modulating p73a functions. In addition, there are B70 amino acids beyond SAM (post-SAM domain) and they may also be involved in regulating p73a activities. Indeed, deletion of the post-SAM domain from p73a enhances its transactivation potential .
p73 as a DNA-binding transcriptional activator is clearly demonstrated. However, the mechanism by which p73 mediates transactivation remains unclear. For example, although p300/CBP was shown to act as a coactivator of p73-mediated transactivation , the HAT function of p300/CBP appears to be dispensable (Zeng et al., 2001 ). Thus, it remains possible that p73 recruits a different coactivator for targeted histone acetylation required for transcription activation, while p300/CBP could play a different role in stimulating p73-dependent transcription such as by bridging p73 and basal transcription machinery. In addition, there are multiple forms of p73 and their activities could be differentially regulated. We have begun to address some of these issues. In this study, we show that PCAF physically associates with p73 in vitro and in the cell and such an association is important for p73-mediated transactivation. We also show that the HAT domain of PCAF is important for coactivation of p53-responsive reporter genes and the induction of apoptosis. Our results indicate that PCAF is a p73 coactivator, which is likely recruited to p73 target promoters for region-specific nucleosomal acetylation, leading to the activation of p73 target genes.
Results

p73 binds to PCAF in vitro and in vivo
Yeast two-hybrid assays were employed to test the interaction between p73a, b and PCAF. As shown in Figure 1a , the presence of either Gal4-AD-p73a (sectors 3 and 4) or Gal4-AD-p73b (sectors 5 and 6) with Gal4-BD-PCAF in yeast led to its growth on medium lacking histidine, but not when Gal4-AD-p73 and empty Gal4-BD plasmids were introduced into yeast (data not shown). As positive and negative controls for the Gal4-BD-PCAF hybrid, PCAF binds to full-length p53 (sectors 1 and 2), but not p53 TAD or DBD (sectors 7-10), consistent with a previous report that PCAF binds to p53 C-terminal domain . Thus, p73a and p73b bind to PCAF specifically in yeast.
To confirm these results, we examined the p73-PCAF interaction using immunoprecipitation (IP) and glutathione S-transferase (GST) pull-down assays with purified recombinant GST-p73 and PCAF proteins. We performed IP by incubating anti-GST antibody, protein-G agarose and equal amounts of GST or GST-p73a. Precipitated proteins were analysed by Western blot (WB). As seen in Figure 1b , PCAF is coprecipitated with GST-p73a fusion (lane 1), but not with GST (lane 2), indicating a direct interaction between p73 and PCAF in vitro. We then examined PCAF-p73 interaction in vivo. Plasmids HA-p73 and Flag-PCAF were transfected into Soas-2 or HeLa cells. Figure 1c indicates that HA-p73a was precipitated with Flag-PCAF using anti-Flag antibody (lane 4), but not when there was no Flag-PCAF cotransfection (lane 3). Lane 1 shows the expression of HA-p73a in transfected cells. Conversely, PCAF was coprecipitated with both HAp73a and HA-p73b (Figure 1d , lanes 4 and 5), and anti-HA antibody did not cross-react with PCAF (lane 3). Lane 1 shows the purified Flag-PCAF as WB positive control. The presence of HA-p73a and b in the immunoprecipitates is shown in the left portion of Figure 1d . Finally, in human embryonic kidney 293 cells, endogenous PCAF was coprecipitated with endogenous p73 when anti-p73 mouse monoclonal antibodies were used in IP (Figure 1e , lane 4), but not in mock IP using irrelevant mouse monoclonal antibody (lane 3). To ensure that p73 was precipitated along with PCAF in the IP, the same membrane was stripped with sodium hydroxide, and reprobed with the same anti-p73 antibody used for IP. As shown in the right panel of Figure 1e , several species of p73 were precipitated along with PCAF (lane 4), but not in mock IP (lane 3). We then performed reciprocal IP using anti-PCAF polyclonal antibody in 293 whole-cell extracts (WCEs). As shown in Figure 1f , both p73a and b (judged by sizes) were coprecipitated along with PCAF (indicated with arrows), but not in mock IP using an irrelevant rabbit polyclonal antibody (anti-luciferase; two crossreactive bands denoted with a dot were present in the control IP, but their sizes are different from p73a or b). Substantial amount of cellular p73 was coprecipitated with PCAF, as the amount of p73 present in 2% of input material for IP was undetectable, but they were clearly visible in anti-PCAF immunoprecipitates. If p73 was quantitatively precipitated by the anti-p73 antibody, the amount of p73 shown in lane 2 of Figure 1f would be B25% of total inputting p73. We estimated that B5% of cellular p73a and b might exist in complexes with PCAF. To ensure that the anti-PCAF antibody used for IP can efficiently precipitate (e and f) p73 and PCAF interacts in vivo. WCE of human embryonic kidney cell line 293 was subjected to IP using monoclonal anti-p73 antibody (BioCarta) and the immunoprecipitates were analysed using polyclonal anti-PCAF antibody in WB (left panel). The same membrane was stripped and reprobed with anti-p73 antibody (right panel). In reciprocal IP, anti-PCAF antibody was used and the precipitates were analysed using anti-p73 monoclonal antibody (f). To identify various p73 molecules positively, anti-p73 immunoprecipitates were loaded (lane 2). p73a and b are indicated with arrows and crossreactive bands in control IP are denoted with dots. To ensure that anti-PCAF antibody used for IP effectively precipitated PCAF, the immunoprecipitates of this antibody (lane 7) along with control antibody (lane 8) were analysed using the same anti-PCAF antibody (right, panel f) PCAF itself, we probed PCAF in the immunoprecipitates. As shown in the right panel of Figure 1f , anti-PCAF significantly precipitated PCAF (lane 7) and the control antibody only slightly precipitated PCAF (lane 8). Thus, PCAF binds to p73a and b in vitro and in vivo.
Both TAD and OD of p73 are required for interacting with PCAF
Having determined that p73 binds to PCAF, we then mapped its binding site in the p73 protein. First, four GST-p73 fusion constructs that cover the entire p73a sequence were made (Figure 2a) , and the recombinant proteins were expressed and purified from E. coli. These GST fusion proteins were used for GST pull-down assays. Bound Flag-PCAF was analysed in WB analysis with antibody to the Flag tag. PCAF was significantly retained by the GST-p73 fusion protein F2 that contains the central p73 region (aa 260-430, lane 3), and to a less extent, by the F1 fragment containing the TAD (lane 2), but not by the other two constructs (Figure 2b ). PCAF did not bind to the GST protein alone (Figure 2b , lane 6). The GST and GST-p73 fusion proteins retained in glutathione-Sepharose 4B beads in the assay were detected in WB analysis using antibody to GST (see the lower part of Figure 2b ; note that F2 (B48 kDa) migrated more slowly than anticipated; F1 (B58 kDa), F3 (B40 kDa) and F4 (B33 kDa) migrated in the gel as predicted). To confirm these results, we incubated antiFlag antibody, purified Flag-PCAF with protein-G agarose in the presence of one of the same set of GSTp73 fragments, and the precipitated GST fusion protein was revealed in WB analysis with anti-GST antibody. As shown in Figure 2c , PCAF-F2 interaction was confirmed (lane 3); other fragments did not significantly bind to PCAF (data not shown). Next, we set to determine more precisely the PCAFbinding domain(s) of p73. Gal4-BD-PCAF hybrid was used to test its interaction with Gal4-AD hybrid of various p73 domains. As shown in Figure 2d , significant interaction between PCAF and p73 occurs only when both p73's TAD and OD are present (sectors 7 and 10). Together with the results of GST pull-down and IP assays shown in Figure 2 , the OD of p73 may be the major determinant of p73's binding to PCAF and the TAD may also contact PCAF. To assess further the role of OD in binding to PCAF, we mutated extensively the conserved residues of OD. Point mutations within the OD significantly reduced p73-PCAF interaction (see Figure 4 ). Consistently, we showed previously that PCAF binds to p53 C-terminal domain encompassing the conserved OD. Collectively, we conclude that both TAD and OD of p73 are required for its binding to PCAF.
PCAF's HAT domain is essential for its binding to p73
We also determined the domains within PCAF that are important for binding to p73. Yeast two-hybrid assays using Gald4-BD hybrids containing various regions of PCAF and Gal4-AD-p73a were performed. As shown in Figure 2e and f, any PCAF constructs without the HAT domain were defective in binding to p73. However, the HAT domain alone was not enough for interacting with p73. Consistently, when the conserved C-terminal domain including the Bromo motif or the N-terminal 464 amino acids were deleted, binding to p73 by PCAF was significantly reduced, judged by the yeast growth phenotype (compare sectors 2 and 3 with 1, Figure 2e and f). Thus, the HAT domain is essential for PCAFp73 interaction and the N-terminal domain and Bromo domain may enhance this interaction.
PCAF stimulates p73-dependent transcription
PCAF is a transcription coactivator that enhances the activity of numerous activators (Schiltz and Nakatani, 2000; Sterner and Berger, 2000) . To determine the functional relevance of the PCAF-p73 interaction, we examined whether PCAF affects p73-mediated transactivation. The p53-responsive luciferase reporter PG13-Luc (el-Deiry et al., 1993) was transfected along with selected plasmids into p53-deficient Saos-2 cells. As shown in Figure 3a , transfection of PCAF stimulated reporter activity slightly. Interestingly, p73b transfection markedly stimulated the reporter activity, and cotransfection of PCAF dramatically enhanced the reporter activity. Similarly, p73a also stimulated the transcription of this reporter (see Figure 4a ). Consistent with previous reports (De Laurenzi et al., 1998; Ueda et al., 1999 Ueda et al., , 2000 Minty et al., 2000) , our data also indicate that p73b may be a more potent transactivator than p73a for some p53-responsive genes ( Figure 4a ). As PCAF's HAT domain is essential for its interaction with p73 ( Figure 2e and f), we wondered whether the HAT domain is also required for p73b-mediated transactivation. Two HAT-deficient mutants of PCAF, PCAFD HAT1 (D579-608) and PCAFDHAT2 (D608-623), were used for cotransfection. Data presented in Figure 3b indicate that both mutants did not significantly affect p73b-mediated transactivation. These observations could not be due to the lower expression of the mutants, as the protein levels of these mutants were comparable to that of wild-type PCAF in the transfected cells ( Figure 3b) . Also, the level of expression of p73b in the transfected was similar (Figure 3b lower right panel); thus the higher luciferase activity was not simply due to higher expression of p73b. Therefore, the HAT domain of PCAF is important for p73b-mediated transactivation, suggesting that p73 recruits PCAF through direct physical interaction.
To test the effects of PCAF on p53-responsive genes further, we used the pWAF1-Luc reporter, which contains the p21/cip1/WAF1 gene promoter with two p53-binding sites (denoted with BS1 and BS2 in panel c). Consistent with published results (De Laurenzi et al., 1998; Zhu et al., 1998) , both p73a and b can stimulate pWAF1-Luc reporter ( Figure 3c ). Interestingly, transfection of PCAF alone significantly enhanced the reporter activity, probably due to PCAF-mediated coactivation of MyoD or other transcription factor-dependent p21 expression (Puri et al., 1997; Sartorelli et al., 1999) . The data also indicate that PCAF moderately increased both p73a-and b-mediated transactivation of pWAF1 ( Figure 3c ). Similar results were obtained for other p53-responsive promoters (data not shown).
Since PCAF alone can stimulate transcription from p21 promoter, it is important to test whether PCAF is tethered to the promoter by p73 or through other factors that bind to DNA elements within the promoter. To this end, we first modified the p21 promoter by deleting the p53-binding site 1 (BS1) in the luciferase reporter construct. Both p73a and b as well as PCAF were responsive to this modified p21 promoter (Figure 3d ). Importantly, cotransfection of p73a/b with PCAF led to enhanced reporter activity. We then mutated p53-binding site 2 (BS2) as indicated in Figure 3e . As expected, p73a/b did not activate transcription from this mutated p21 promoter that does not contain any p53-binding sequence. Significantly, PCAF can no longer stimulate the reporter activity and cotransfection of PCAF with p73a or b had no effect (Figure 3e ). Thus, coactivation of p21 promoter by PCAF required p53-binding sites. Finally, we examined the effects of p73 and PCAF on p21 expression in vivo. PCAF or its HAT-deficient mutant PCAFDHAT1 was transfected alone or together with p73a, b or p53. To enrich transfected cells, the pBabe-puromycin vector was cotransfected and the cells were cultured in a medium containing puromycin. The surviving cells were analysed for p21 expression by WB. Data presented in Figure 3f indicate that PCAF transfection significantly increased p21 protein levels (compare lane 2 with 1), consistent with the results of reporter assays shown in Figure 3c . Cotransfection of PCAF with p53 or p73a did not noticeably augment p21 levels above that from PCAF transfection alone (compare lane 3 or 4 with 2). Strikingly, cotransfection of PCAF with p73b markedly increased levels of p21 above that in PCAF-transfected cells (lane 5). In addition, although the p21 levels were higher in PCAFDHAT1-transfected cells than that of nontransfected cells (compare lane 7 with 1), neither p73b, p73a nor p53 further enhanced p21 expression (lanes 7-9). Thus, PCAF and p73b act synergistically in stimulating p21 transcription and PCAF's HAT domain is required for this effect. Collectively, our data demonstrate that PCAF is a coactivator of p73-mediated transactivation and such a coactivation requires the PCAF HAT domain as well as a specific DNA sequence. PCAF is likely recruited to chromatin-bound p73, leading to histone acetylation and transcription activation.
Interaction of p73 with PCAF is essential to p73's transactivation function
To substantiate the role of PCAF in p73-mediated transcription further, we sought to identify p73 mutants that do not bind to PCAF, as such mutants may have impaired transactivation function. We first tested the transactivation activity of a set of p73 mutants with various functional domains as depicted in Figure 2d . These mutants were cloned into pExchnage-3B under the control of the CMV promoter and all contain Nterminal Flag tag. These constructs along with reporters were transfected into Saos-2 cells and the luciferase activities were measured in the transfected cell lysates. As shown in Figure 4a , there is a clear correlation between transactivation activity and binding of p73 to PCAF. Mutants that do not bind to PCAF are completely devoid of transactivation function. As both TAD and OD are required for p73 to bind to PCAF, one could argue that mutants lacking OD may no longer form tetramer; consequently, they may lose their transactivation potential as a direct result of the inability to form a tetramer. However, mutant TAD þ DBD þ PXXP þ OD þ SP has intact OD, and in our yeast two-hybrid assay, DBD þ PXXP þ OD þ SP fused with Gal4-BD was able to interact with p73a, b and mutants that still have OD, but not with the mutants that do not have OD (data no shown). Thus, mutant TAD þ DBD þ PXXP þ OD þ SP may still possess the ability to oligomerize, and its inability to activate transcription is likely due to the failure to bind to PCAF. Taken together, these data indicate that interaction of p73 with PCAF is important for p73's transactivation function.
Since OD of p73 is essential for binding to PCAF, we carried out site-directed mutagenesis to pinpoint important residues within OD that are required for binding to PCAF. We showed previously that PCAF also binds to p53 within a region that contains OD . Thus, the conserved residues between p73 and p53 (white letters in black background in Figure 4b ) may be important for interacting with PCAF. We first mutated these conserved residues individually to alanine, and then assayed the interaction of such point mutants with PCAF in the yeast two-hybrid system. As shown in Figure 4c , all the point mutants can still bind to PCAF, although it appeared that mutation of the negatively charged residues (d or e) into alanine reduced the ability of the mutants to support yeast growth in a medium lacking adenine (ÀAde sectors 4, 13, 15 and 17 in Figure 4c ). We therefore mutated several Es simultaneously into A. Indeed, such mutants reduced yeast growth in a medium lacking histidine (compare GST pull-down assay indicating that PCAF binds to p73a F2 and F1 fragments. Purified Flag-PCAF and GST-p73 fusion proteins (F1-F4) were incubated with glutathione-Sepharose 4B beads and the mixtures were washed extensively. The proteins that remained in the beads were subjected to SDS-PAGE and WB using indicated antibodies. The upper panel shows Flag-PCAF that associated with the GST-p73 fusion proteins, and the lower panel shows beads-bound GST or its fusion with p73a fragments. (c) In vitro IP assay of p73-PCAF interaction. The p73 fragment F2 was incubated with purified Flag-PCAF and subjected to IP and WB using indicated antibody. (d) Both TAD and OD of p73 are required for binding to PCAF in yeast. Yeast two-hybrid assays were performed using Gal4-BD-PCAF and Gal4-AD hybrids of various p73 domains as indicated. Yeast growth was scored in a medium lacking histidine, but in the presence of 3-AT. (e) The HAT-domain of PCAF is essential for binding of PCAF to p73. Fusion of Gal4-BD with a specified PCAF domain as indicated was cotransformed with Gal4-AD and p73a fusion, and yeast growth was scored as in ( Figure 4d ) and they could not support yeast growth at all in a medium lacking adenine (data not shown). In addition, mutants that terminated within OD (1-364 and 1-376) completely lost the ability to bind to PCAF (sectors 3 and 4). These mutants were then tested for their ability to transactivate the p53-responsive reporter gene. As shown in Figure 4e , truncation mutants p73 (1-364, p73T1) and p73 (1-378, p73T2) had no transactivation activity, whereas triple mutants p73 E3A (E363/373/376A) and quadruple mutant E4A (E363/366/373/376A) had reduced transactivation activity. Furthermore, cotransfection of PCAF was able to further stimulate p73b's transactivation activity, but had virtually no effects on E3A and E4A's transactivation function (Figure 4e ). Taken together, our results demonstrate an essential role for p73-PCAF interaction in p73-mediated transcription.
PCAF-specific siRNA reduces p73-mediated transactivation
The results described above support the fact that PCAF is a coactivator of p73-dependent transcription. If this is indeed the case, it would be anticipated that reduced expression of PCAF would decrease p73-mediated transactivation. To test this, we employed the siRNA technology and took advantage of the PCAF-specific siRNA that has been documented to be effective in reducing PCAF protein levels (Bres et al., 2002) . Saos2 cells were first transfected with PCAF siRNA or control siRNA, and then with PG13-Luc reporter alone or together with various p73 constructs. As shown in Figure 5 , PCAF siRNA markedly reduced p73-mediated transactivation. In most cases, the reporter activities in PCAF siRNA-transfected cells were less than 50% of that in cells transfected with control siRNA. The effect was highly specific because PCAF siRNA had no effect on reporter activities that do not depend on PCAF (e.g., in cells transfected with p73 TAD þ DBD). These data further demonstrate an important role for PCAF in regulating p73-dependent transcription.
PCAF stimulates p73-dependent apoptosis in vivo
Exogenous expression of p73 can lead to cell-cycle arrest or apoptosis (Jost et al., 1997; Kaghad et al., 1997; Levrero et al., 2000; Zhu et al., 2001) . To assess whether PCAF modulates these two biological efforts of p73, we examined the percentage of apoptotic cells in transiently transfected Saos-2 cells using various combinations of plasmids. As judged by apoptotic morphology, elevated apoptosis in p73a-and b-transfected cells was found relative to that in control transfection, and PCAF can further increase apoptotic index in these experiments (Figure 6a ). TUNEL assays yielded essentially the same results (data not shown). We then performed colony formation assays in p53-deficient non-small-cell lung carcinoma H1299 cells. The dose of neomycin-resistant gene and the transfection conditions were kept the same in all transfections. Thus, the number of G418-resistant colonies is a reflection of growth arrest and apoptosis exerted by the transfected plasmids in each transfection. PCAF moderately reduced the number of colonies, whereas the HAT-deficient mutants (PCAFDHAT1 and 2) had virtually no effects on colony formation ( Figure  6b and c). p73a transfection reduced the colony number to about a half of that in the control, and PCAF cotransfection further decreased the colony number to only B20% of that in the control transfection. Introduction of p73b-expression plasmid significantly reduced the colony number (B40% of that in the control), and PCAF cotransfection led to further reduction. In addition, whereas HAT-deficient mutants moderately enhanced p73a-mediated reduction in colony formation, these mutants did not influence p73b-mediated effects, suggesting that the HAT activity of PCAF may be required for p73, especially p73b-mediated efforts on colony formation. These results support the notion that both p73a and b play a role in cell growth regulation, fully consistent with previous reports (Kaghad et al., 1997; Levrero et al., 2000; Yang and McKeon, 2000) . Further, these data support a functional interaction between PCAF and both p73a and b in cell-cycle control and apoptosis, likely through their combined efforts in the activation of genes involved in these processes. Figure 3 PCAF is a coactivator of p73-mediated transactivation. (a) Firefly luciferase reporter PG13-Luc containing multiple copies of consensus p53-binding sites along with internal control Renilla luciferase reporter (1 mg each) was transfected with indicated plasmids (pcDNA: pcDNA3.1, PCAF: pCX-Flag-PCAF, p73b: pcDNA3-HA-p73b) into Saos-2 cells (the amount of plasmid DNA was: PCAF and its mutants: 1 mg, p73b and pcDNA: 0.1 mg; carrier plasmid DNA was added to balance the total DNA quantity in each transfection), and dual luciferase assays were carried out. The firefly luciferase activity was normalized against Renilla luciferase activity, and the luciferase activity relative to control (pcDNA) was plotted. (b) The HAT domain of PCAF is required for stimulating p73b-mediated transactivation. PCAF HAT mutants (DHAT1, Daa 579-608 and DHAT2, Daa 608-623, 1 mg each) were used in lieu of PCAF in the reporter assays. The reporters and other plasmids used for transfection were as in (a). The expression of PCAF, its HAT mutants and p73b in the transfected cells was verified in WB using anti-Flag and anti-HA antibody, respectively. (c) PCAF as coactivator of p73a and b for the p21/cip1/WAF1 promoter. The assays were as in (a) except that the firefly luciferase reporter was pWAF1-Luc that contains the p21/cip1/WAF1 gene promoter with two p53-binding sites (BS1 and BS2, whose positions relative to the transcription start site are depicted). (d) Luciferase assays using pWAF1DBS1-Luc. The BS1 of the pWAF1 promoter was deleted and luciferase assays were as in (a). (e) Stimulation of p21 transcription by PCAF requires p53-binding sites. BS2 was mutated as depicted and the mutant reporter construct was used in the luciferase assays. (f) PCAF and p73b synergistically enhance p21 expression in vivo. Saos2 cells were transfected with indicated plasmids along with pBabe-puromycin. Transfected cells were enriched with puromycin selection. An equal amount of total proteins (10 mg) was loaded in each lane and p21 expression in the transfected cells was determined with WB using antibody to p21 (C19). The same blot was stripped and reprobed with antibody to a-tubulin (lower panel)
Discussion
PCAF is a coactivator that enhances the activity of numerous other activators and proteins involved in transcription, including class II transactivator (CIITA) (Spilianakis et al., 2000; Harton et al., 2001) , MyoD (Sartorelli et al., 1999; Polesskaya et al., 2000) , E2F1 (Martinez-Balbas et al., 2000) , TAL1/SCL (Huang et al., 2000) , RXR-RAR nuclear receptors (Blanco et al., 1998) , E1A (Zhang et al., 2000) and TAF (Muth et al., 2001 ) and the architectural protein HMGI(Y) (Munshi et al., 2001) . PCAF can function alone or together with p300/CBP coactivators through their interaction depending on target promoters. Interestingly, the HAT activity of p300/CBP and PCAF is often differentially used in transcription activation. For example, although both p300/CBP and PCAF are the required cofactors for MyoD, only the HAT activity of PCAF, but not that of p300/CBP, is necessary for MyoD activity and muscle differentiation (Puri et al., 1997) . Moreover, PCAF acetylates MyoD, which augments MyoD's DNA-binding activity (Sartorelli et al., 1999) . Similarly, the HAT activity of PCAF rather than that of p300/CPB is required for transcription mediated by the retinoic acid receptors (RARs) (Korzus et al., 1998) . In contrast, CREB-and STAT-1-mediated transactivation relies on the HAT activity of p300/CBP (Korzus et al., 1998) . Nonetheless, both PCAF and p300/CBP acetylate histones, which are thought to be required for general transcription (Struhl, 1998; Brown et al., 2000) . Thus, different activators could in principle recruit either p300/CBP or PCAF for targeted nucleosomal acetylation of specific genes. In addition, acetylation of the architectural protein HMGI(Y) by both PCAF and p300/CBP plays distinct roles in the coordination of transcriptional switch of the interferon-b gene expression (Munshi et al., 2001) . Zeng et al. (2000) showed that p300/CBP is a coactivator for p73-mediated transactivation. The TAD of p73 binds to the CH1 domain of p300/CBP and this interaction is necessary for coactivation. Interestingly, the p300/CBP HAT activity does not appear to be required for stimulating p73-mediated transactivation (Zeng et al., 2001) . Here, we show that PCAF also functions as a potent coactivator of p73 and the interaction between p73 and PCAF is essential for p73-mediated transactivation. Furthermore, the HAT domain of PCAF is necessary for this activity. Thus, like MyoD and RARs, p73 uses both PCAF and p300/CBP as coactivators and only the HAT activity of PCAF may be required for p73-mediated transactivation. It remains to be determined whether p73 recruits p300/CBP and PCAF concomitantly for activating its target genes or differentially employs these coactivators in a genespecific manner. p300/CBP is also the coactivator for p53-mediated transactivation (Avantaggiati et al., 1997; . Whether PCAF is also a p53 coactivator has not been clearly established. For example, we failed to detect coactivation of PCAF and p53 in reporter assays (our unpublished data). Data shown in Figure 3f also suggest that PCAF does not appreciably enhance p53's transactivation on p21 promoter. Nonetheless, PCAF binds to and acetylates p53 . Therefore, both p300/CBP and PCAF may be important regulators of p53 activity. In principle, PCAF and p300/CBP may be differentially recruited by p53 or p73, depending on cisor transacting elements in specific genes. Although the DBD is the most conserved domain between p53 and p73, and they bind to the same consensus sequence, p53 and p73 target genes may not overlap entirely. For example, only six out of 36 p53-induced genes were significantly induced by p73a (Yu et al., 1999) . In contrast, both p73a and b are much more potent in activating the 14-3-3s gene than p53 (Zhu et al., 1998) . Figure 4 Interaction with PCAF is required for p73-mediated transcription. (a) Reporter assay of various p73 mutants. The expression vector carrying various p73 constructs as indicated was transfected into Saos-2 cells along with reporters and the normalized luciferase activity was plotted as described in Figure 3 . The amount of each reporter and p73 construct used in each transfection was 0.5 and 0.1 mg, respectively. (b) Sequence alignment of p53 and p73 OD. The conserved residues are depicted as white letters in black background and the position of the start and end amino acid is denoted. (c) Yeast two-hybrid assays of PCAF and p73a OD mutants. The mutations were created using Quick-change protocol. Gal4-BD-PCAF and Gal4-AD-p73a mutants were introduced into yeast. The yeast colonies were restreaked on a medium lacking histidine, but with 5 mm 3-AT (ÀHis) or medium lacking adenine (-Ade). The Gal4-AD-p73a mutant used in each sector is depicted in the lower part of the panel. (d) The negatively charged residues in p73 OD are involved in interaction with PCAF. p73 mutants (truncation and multiple point mutations) as indicated were assayed for interaction with PCAF and the yeast growth was scored in a medium lacking histidine, but with 5 mm 3-AT (ÀHis). All these mutants did not support growth at all in medium lacking adenine when they were individually introduced into yeast along with Gal4-BD-PCAF. Figure 5 PCAF-specific siRNA inhibits p73-mediated transactivation. Saos2 cells were transfected with siRNA targeting GFP or PCAF, and 24 h later, p53-responsive luciferase reporter and control reporter were transfected alone or with various p73 constructs as indicated. Cells were harvested 48 h later after siRNA transfection and processed for dual luciferse assays. Relative luciferase activities to that of cells transfected with reporters only were plotted with standard deviation in two independent experiments. White bars: GFP siRNA transfection; black bars: PCAF siRNA transfection
In addition, whereas p53 is induced in diverse stress conditions, p73 can only be induced by a subset of agents, such as ionized irradiation, cisplatin and doxorubicin (Agami et al., 1999; Gong et al., 1999; Yuan et al., 1999; Costanzo et al., 2002) , but not UV and actinomycin D (Kaghad et al., 1997) . In our reporter assays, Bax and p53AIP promoters are more responsive to p73 than p21/WAF1 and MDM2 (data not shown). Therefore, an important issue in understanding p73 biology is to identify specific target genes for p73. The knowledge that PCAF is a coactivator of p73-dependent transactivation may facilitate this task.
Our results indicate that p73 constructs lacking C-terminal RD (aa 555-636) had higher transactivation potential than wild-type p73a (see Figure 4) , in agreement with a previous report . However, contrary to another previous report , our results do not support the identification of a second TAD within aa 384-487. Instead, p73 mutant spanning amino acids from 1 to 487 has no transactivation activity (Figure 4a ). Curiously, this mutant differs from wild-type p73b by only a truncation of 12 amino acids from the C-terminus. Thus, the extreme C-terminal sequence of p73b is critical for its transactivation function. This sequence may be important to maintain the proper tertiary structure of p73b or it may be important for binding to other cellular factors. In view of the fact that the mutant lacking this sequence could not bind to PCAF, and this sequence does not appear to be directly involved in binding to PCAF, it is more likely that the sequence may be important to maintain a three-dimensional conformation of p73b that is required for its binding to PCAF, thus its transactivation function.
We show here that both TAD and OD of p73 are required for its binding to PCAF, which may suggest that PCAF binds to TAD of the tetramerized p73, without direct contact with OD. However, our data indicate that there is direct interaction of OD with PCAF, as in the GST pull-down assay, PCAF was able to bind to a fragment spanning OD and a part of DBD (Figure 2) , and in the yeast two-hybrid assays, point mutations of the conserved residues within OD reduce PCAF-p73 interaction. Mutation of the negatively charged residues into alanine unlikely affects tetramer formation as these residues face away from the tetramer interface in the three-dimensional structure of p53 tetramer (Jeffrey et al., 1995) . Therefore, PCAF may contact multiple sites of p73 tetramer. Such a mode of interaction could potentially play an important role in mediating p73-dependent transcription. For example, PCAF may only recognize transcription-competent p73 tetramer when it is assembled at specific promoters.
The HAT domain of PCAF is essential for its binding to p73 (Figure 2e and f), and is also required for stimulating p73b-mediated transactivation (Figure 3b ). Thus, a physical interaction between PCAF and p73 underlies their coactivation of transcription. Additionally, our unpublished data indicate that p73 is a substrate of PCAF acetylation, and the C-terminus of p73a was significantly acetylated in vitro. We also determined that direct acetylation of p73 by PCAF did not significantly affect p73's transactivation function in reporter assays (data not shown). Thus, whether or not acetylation of p73 by PCAF affects p73's activity is unknown at present. It is noteworthy that p53 acetylation per se might not be necessary for p53-mediated transactivation; rather, DNA-bound p53 recruits p300/ CBP, leading to targeted nucleosomal acetylation and transcription activation (Espinosa and Emerson, 2001 ). p73 may act in the same way by recruiting PCAF to specific promoters for targeted acetylation and transcription activation. Nonetheless, direct acetylation of p73 by PCAF could modulate p73's transactivation activity, for example, when a cell is exposed to cellular stresses. Indeed, it was shown recently that several lysine residues within the DBD of p73 are only weakly acetylated by p300 in the absence of stress, but such an acetylation is markedly increased in cells treated with DNA-damaging agents (Costanzo et al., 2002) . Furthermore, acetylation of p73 at these sites appears to enhance selectively transcription of proapoptotic gene p53AIP1, but has little effect on the transcription of gene for cell-cycle inhibitor p21 (Costanzo et al., 2002) .
Materials and methods
Plasmids
The pcDNA3-HA-p73a and pcDNA3-HA-p73b plasmids were obtained from M Kaghad. PG13-Luc and pWAF1-Luc were provided by B Vogelstein. pGBDU-PCAF, pGAD-p73a, pGAD-p73b, pGEX-4T-1-p73a, pGEX-4T-1-p73F1 (aa 1-249), pGEX-4T-1-p73F2 (aa 260-430), pGEX-4T-3-p73F3 (aa 430-560) and pGEX-4T-3-p73F4 (aa 560-636), pCX-Flag-PCAF, pCX-Flag-PCAFDHAT1 (aa 579-608 were deleted) and pCX-Flag-PCAFDHAT2 (aa 608-623 were deleted) were constructed. p73 mutants with different domains (see Figures 2 and 4) were generated by PCR and cloned into pGAD-C1, and pExchange-3B (Stratagene), in which all constructs are tagged with Flag. Site-directed mutagenesis was performed using Quick Change protocol (Stratagene).
Cell culture and antibodies
Human cervical carcinoma HeLa and human osteosarcoma Saos-2 were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum. Nonsmall-cell lung carcinoma H1299 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. Antibodies used in this study included mouse monoclonal anti-HA (Roche Molecular Biochemicals) and Flag (Sigma), antip73 rabbit polyclonal antibody (H-79), anti-p21 rabbit polyclonal antibody (C19), anti-GFP antibody (Santa Cruz Biotechnology), anti-PCAF rabbit polyclonal antibody (Upstate Biotechnology) and anti-p73a/b monoclonal antibody (BioCarta, cocktail of clones ER-13, ER-15 and GC-15).
Purification of GST-p73 fusion proteins
Various GST-p73 fusion proteins were expressed and purified from E. coli. Briefly, bacterial pellet in cold phosphatebuffered saline (PBS, pH 7.4) was sonicated, and Triton X-100 was added to the suspension to 1%. The mixture was incubated for 15 min and then centrifuged at 10 000 rpm for 10 min. The supernatant was filtered through 0.45 mm filter and then mixed with glutathione-Sepharose 4B resin (Amersham) that was washed with PBS, and the mixture was rotated for at least 2 h at 41C. The resin was collected and washed four times with PBS and the fusion protein was eluted with elution buffer (7.5 mm reduced glutathione in PBS).
GST pull-down assay
The purified Flag-tagged PCAF was incubated with glutathione-Sepharose 4B beads (50% slurry) containing approximately 0.5 mg of various GST-p73 fusion proteins in PBS. At 1 h after incubation at 41C, the mixtures were washed three times with PBS and once with RIPA buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS) and 1% (wt/vol) sodium deoxycholate). Bound proteins were analysed on a 10% SDS-polyacrylamide gel and detected by WB analysis using the anti-Flag antibody to assay p73-PCAF interaction and to map the PCAF-binding site on p73.
Coimmunoprecipitation and WB analysis
In each IP experiment, approximately 0.5-1 mg of each purified protein was incubated with an appropriate antibody in buffer B (20 mm Tris-HCl, pH 8.0, 5 mm MgCl 2 , 10% glycerol, 0.1% NP-40, 150 mm KCl) with protease inhibitors (10 mg/ml pepstatin, 5 mg/ml leupepstatin, 20 mg/ml aprotinin and 1 mm PMSF) for at least 1 h with rotation at 41C. The amount of antibody used per IP assay is different depending on specific antibodies; the typical amount is 1 mg. Protein-G agarose beads (30 ml; Roche Molecular Biochemicals) were added into the protein-antibody mixture and incubated at 41C for at least 1 h with rotation. The beads were collected by centrifugation and washed four times with buffer B and once with RIPA. The beads were collected by centrifugation and mixed with 30 ml of 1 Â SDS loading buffer. The precipitated proteins were subjected to SDS-PAGE and transferred onto a nitrocellulose membrane in 25 mm Tris base-190 mm glycine at 50 V for 2 h at 41C. The coprecipitated proteins were detected in WB using an appropriate antibody with the enhanced chemiluminescence (ECL, Amersham) kit.
To detect p73-PCAF interaction in vivo, Saos-2 or HeLa cells were transfected with 2 mg of pCX-Flag-PCAF along with 2 mg of pcDNA3, pcDNA3-HA-p73a or pcDNA3-HA-p73b using Superfect reagent (Qiagen). Briefly, Superfect-DNA mixture was layered onto the cells for 3 h, and then replaced with fresh complete DMEM. Cells were harvested 48 h posttransfection. Cells were lysed with buffer B, and the lysates were precleared with 20 ml of protein-G agarose and then incubated for 3 h at 41C with fresh protein-G beads and 2 mg of anti-HA (for HA-tagged p73) or anti-Flag (for Flag-tagged PCAF) antibodies. The beads were collected by centrifugation and washed four times with buffer B. The precipitates were analysed with SDS-PAGE and WB. Coprecipitation of endogenous p73 and PCAF was carried out using mouse monoclonal anti-p73a/b (BioCarta) and rabbit polyclonal anti-PCAF antibodies in 293 WCEs.
Yeast two-hybrid assay p73a, p73b and various mutants were fused to Gal4 activation domain (AD) in plasmids pGAD-C(x), and PCAF was fused with the Gal4 DBD in pGBDU-C(x). The yeast strain PJ69-4A was used for the two-hybrid assay as described previously (James et al., 1996) . The pGAD-p73 and pGBDU-PCAF were introduced into the host yeast by the standard lithium acetate transformation method. To test potential protein-protein interaction, transformants were screened for growth in a medium lacking histidine, but in the presence of 5 mm 3-aminotriazol (3-AT) (His þ phenotype) or lacking adenine (Ade þ phenotype).
Luciferase assays
Saos-2 cells (50% confluent) were transfected with the various firefly luciferase (Luc) reporters (1 mg each) including PG13, which contains multiple copies of the p53-binding sequence, or pWAF1-Luc (1 mg), which contains a fragment from the p21/ CIP1/WAF1 gene promoter (el-Deiry et al., 1993) , together with a CMV promoter-driven Renilla luciferase (RLuc) reporter plasmid (1 mg) and a combination of different plasmids as indicated in various figures using Superfect reagent. Irrelevant plasmids were added so that the total amount of DNA transfected was kept the same in each transfection. Cells were harvested for luciferase assays 24 h post-transfection using dual luciferase assay regents (Promega) according to the protocol supplied by the manufacturer. Firefly luciferase activity was normalized against RLuc activity.
For testing the effects of siRNA on reporter activities, synthetic 21-nt RNA duplexes (Dharmacon) were used. Control GFP siRNA duplex (forward: 5 0 -GGC UAC GUC CAG GAG CGC ACC, reverse: 5 0 -UGC GCU CCU GGA CGU AGC CUU) or PCAF siRNA duplex (forward: 5 0 -UCG CCG UGA AGA AAG CGC ATT-3 0 ; reverse: 5 0 -UGC GCU UUC UUC ACG GCG ATT-3 0 , as reported by Bres et al., 2002) was transfected into Saos2 cells using Lipofectamine 2000 reagent according to the manufacturer's protocol (Invitrogen). Luciferase reporters alone or with different p73 constructs were transfected 24 h after siRNA transfection, and 24 h later, cells were harvested for dual luciferase assays.
Effect of PCAF and p73 on p21 expression in vivo Saos2 cells were transfected with PCAF or PCAFDHAT1 plasmid alone or in combination with p53, p73a or b construct (0.5 mg of each plasmid). To select for transfected cells, pBabe-puromycin (0.2 mg) was included in all transfections. At 24 h after transfection, the culture medium was changed from a normal medium to one containing 2 mg/ml puromycin. After 24 h of selection, floating cells were removed and the adherent cells were washed once with PBS. The cells were lysed in buffer B supplemented with protease inhibitors and the protein concentration of the extracts was determined using the Bradford method. An equal amount of protein from each transfection was loaded for SDS-PAGE and WB using anti-p21 antibody (C19). The membrane was stripped and reprobed with antibody to a-tubulin to ensure equal loading.
Apoptotic assay
Saos-2 cells (40% confluent) were transfected with the pEGFP plasmid (1 mg) together with a combination of various expression plasmids as indicated in different experiments. Empty vectors were used as controls. The morphology of cells expressing GFP was analysed under a fluorescence microscope 32 h after transfection. Apoptotic cells were identified by their rounded and shrunken morphology with condensed nuclei in contrast to the spread-out appearance of nonapoptotic cells, counted on a blind basis, and presented as a percentage of the total population of fluorescent cells. TUNEL assay was performed using in situ Cell Death Detection kit (Roche).
Colony formation assay
H1299 cells (40% confluent) were transfected using Superfect reagent with a combination of various plasmids as indicated in specific assays. An equal dose of neomycin resistant gene in each transfection was strictly maintained. Cells were split in triplicate and grown under G418 (0.4 mg/ml) selection. G418-resistant colonies were selected by growth in complete RPMI 1640 medium containing G418 for 2 weeks. The G418-resistant colonies were then stained with Giemsa solution (Sigma) and counted. The experiments were repeated at least three times in triplicate.
